Abstract 110P
Background
D3 lymph node dissection or complete mesocolic excision (CME) with central vascular ligation (CVL) is becoming standard procedure in advanced right colon cancer with increasing evidences of its oncologic benefit. However, clear indication has not been declared and evidences to lighten the undetermined area is not satisfactory yet. There is still a controversy whether D3 lymph node dissection is necessary in clinical stage I right colon cancer.
Methods
We retrospectively analyzed clinical stage I right colon cancer patients who underwent radical surgery in three Korea university hospitals from January 2015 to June 2018. We compared surgical complications and short-term oncologic outcome between D2 and D3 lymph node dissections in clinical stage I right colon cancer patients.
Results
602 patients had radical surgery for right colon cancer in the study period and the number of clinical stage I patients was 125 (20.8%). Among 125 patients, D2 lymph node dissection was done in 86 patients (68.8%) and 39 patients underwent D3 lymph node dissection. There was no statistically significant differences in clinicopathologic variables and surgical outcomes between two groups. Up-stagings were found in 15 patients (38.5%) in D3 group and 18 patients (20.9%) in D2 group. There were four recurrences in D2 lymph node dissection group but no recurrences in D3 group. Log-rank test was performed and there was no statistically significant difference in recurrence-free survival rate between two groups (p = 0.2).
Conclusions
There was no significant difference in recurrence-free survival rate between D2 and D3 lymph node dissection in clinical stage I right colon cancer patients. But recurrences had occurred in D2 group. Efforts to make clinical staging more accurate is required and more studies with better quality are needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
371P - Clinical utility of Encyclopedic tumour analysis to treat patients advanced refractory head and neck cancers
Presenter: Rajnish Nagarkar
Session: Poster display session
Resources:
Abstract
372P - Real-world fusion landscape in advanced Chinese pancreatic cancer using next generation sequecing: A multicenter study
Presenter: Yiyu Shen
Session: Poster display session
Resources:
Abstract
373P - Molecular profiling of non-small cell lung cancer (NSCLC) in Asia with targeted next-generation sequencing (NGS): Interim analysis of a co-operative group study (ATORG-001)
Presenter: Aaron Tan
Session: Poster display session
Resources:
Abstract
374P - Circulating tumour DNA (ctDNA) identifies actionable genetic alterations in Middle Eastern and Asian (MEA) patients diagnosed with carcinoma of unknown primary (CUP)
Presenter: Nir Peled
Session: Poster display session
Resources:
Abstract
375P - Whole-exome sequencing of tumour-only samples reveals the association between somatic alterations and clinical features in pancreatic cancer
Presenter: Huixin Lin
Session: Poster display session
Resources:
Abstract
376P - Adoption of molecular testing in breast cancer in a tertiary care center in a developing country
Presenter: Prasanta Dash
Session: Poster display session
Resources:
Abstract
377P - NGS in advanced NSCLC in a developing country: Ready for prime time?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
378P - Germline BRCA1/2 testing: Trend in Tan Tock Seng Hospital Singapore
Presenter: Chia Wei Lim
Session: Poster display session
Resources:
Abstract
379P - Study of germline mutations in high risk cancer patients from a tertiary care center in India
Presenter: Padmaj Kulkarni
Session: Poster display session
Resources:
Abstract
380P - Ventricular–Subventricular zone involvement: A predictive factor for survival in glioblastoma
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract